Lipocine Inc./$LPCN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Ticker
$LPCN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
16
Website
Lipocine Inc. Metrics
BasicAdvanced
$17M
-
-$1.01
1.33
-
Price and volume
Market cap
$17M
Beta
1.33
52-week high
$4.23
52-week low
$2.68
Average daily volume
35K
Financial strength
Current ratio
15.64
Quick ratio
15.31
Total debt to equity
1.801
Profitability
EBITDA (TTM)
-6.42
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-146.13%
Operating margin (TTM)
-176.00%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-17.60%
Return on equity (TTM)
-24.89%
Valuation
Price to revenue (TTM)
4.7
Price to book
0.9
Price to tangible book (TTM)
0.9
Price to free cash flow (TTM)
-3.036
Free cash flow yield (TTM)
-32.93%
Free cash flow per share (TTM)
-1.064
Growth
Revenue change (TTM)
-22.00%
Earnings per share change (TTM)
-40.55%
3-year revenue growth (CAGR)
-38.94%
3-year earnings per share growth (CAGR)
63.70%
10-year earnings per share growth (CAGR)
-27.15%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lipocine Inc. stock?
Lipocine Inc. (LPCN) has a market cap of $17M as of August 01, 2025.
What is the P/E ratio for Lipocine Inc. stock?
The price to earnings (P/E) ratio for Lipocine Inc. (LPCN) stock is 0 as of August 01, 2025.
Does Lipocine Inc. stock pay dividends?
No, Lipocine Inc. (LPCN) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Lipocine Inc. dividend payment date?
Lipocine Inc. (LPCN) stock does not pay dividends to its shareholders.
What is the beta indicator for Lipocine Inc.?
Lipocine Inc. (LPCN) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.